Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

LR Mileshkin; KN Moore; EH Barnes; V Gebski; K Narayan; MT King; N Bradshaw; YC Lee; K Diamante; AW Fyles; W Small; DK Gaffney; P Khaw; S Brooks; JS Thompson; WK Huh; CA Mathews; M Buck; A Suder; TE Lad; IJ Barani; CH Holschneider; S Van Dyk; M Quinn; D Rischin; BJ Monk; MR Stockler

Journal article

Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

LR Mileshkin, KN Moore, EH Barnes, V Gebski, K Narayan, MT King, N Bradshaw, YC Lee, K Diamante, AW Fyles, W Small, DK Gaffney, P Khaw, S Brooks, JS Thompson, WK Huh, CA Mathews, M Buck, A Suder, TE Lad Show all

Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2023

DOI: 10.1016/S1470-2045(23)00147-X

Abstract

Background: Standard treatment for locally advanced cervical cancer is chemoradiotherapy, but many patients relapse and die of metastatic disease. We aimed to determine the effects on survival of adjuvant chemotherapy after chemoradiotherapy. Methods: The OUTBACK trial was a multicentre, open-label, randomised, phase 3 trial done in 157 hospitals in Australia, China, Canada, New Zealand, Saudi Arabia, Singapore, and the USA. Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease), Eastern Coo..

View full abstract